This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring

Early Bird pricing expires in:

  • 00
  • 00
  • 00
  • 00
Delivered In-Person & Digitally
March 28–30, 2022, Basel, SwitzerlandApril 4–6, 2022, Digital Partnering

Buzzard Pharmaceuticals


Buzzard Pharmaceuticals is developing Isunakinra, a potent inhibitor of interleukin-1 alpha and beta signaling. IL-1 is produced by tumor cells and macrophages, leading to increased tumor immunosuppression (MDSCs and M2 macrophages), angiogenesis and metastasis. A phase I/II trial in solid tumor patients will start soon at Baylor (Dallas) where we will assess effects on downstream biomarkers IL-6 and CRP as well as effects on patient tumors in combination with a PD-1 inhibitor.